Irinotecan sucrosofate clinical trials
Also written PEP02 and MM-398.
A product of Irinotecan; its studies count on that page too.
How each study uses irinotecan sucrosofate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the irinotecan sucrosofate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 22 Oct 2015 · ONIVYDE · NDA 207793 (FDA, Drugs@FDA)
- European Union
- 14 Oct 2016 · Onivyde pegylated liposomal (previously Onivyde) · EMEA/H/C/004125 (EMA; as Irinotecan)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
79 studies that test it; most in 2024 (18)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 8 |
| 2019 | 7 |
| 2020 | 3 |
| 2021 | 9 |
| 2022 | 3 |
| 2024 | 18 |
| 2025 | 8 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 20 · Other 59
CSPC Ouyi Pharmaceutical Co., Ltd. (5) · PharmaEngine (5) · Ipsen (4) · National Health Research Institutes, Taiwan (3) · Institut de Recherches Internationales Servier (2) · Federation Francophone de Cancerologie Digestive (2) · AIO-Studien-gGmbH (2) · GERCOR - Multidisciplinary Oncology Cooperative Group (2)
Often tested with
Tested in the same studies.
Fluorouracil (21) · Leucovorin (11) · Oxaliplatin (11) · Bevacizumab (7) · Capecitabine (5) · Paclitaxel (3) · Immune checkpoint inhibitors (3) · Trifluridine tipiracil drug combination (2)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Irinotecan
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 13
Studies that test irinotecan sucrosofate.
- Nov 2026Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTCPhase 2 · Sir Run Run Shaw Hospital
- Dec 2026Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid TumorsPhase 1 · South Plains Oncology Consortium
- Dec 2026Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)Early Phase 1 · SONIRE Therapeutics Inc.
- Dec 2026Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent GliomaPhase 2 · Zhifeng Tian,MD
- Jan 2027Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialPhase 2 · Ming-Yuan Chen
- Mar 2027NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar TrialPhase 2 · Roswell Park Cancer Institute
- Apr 2027Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing SarcomaPhase 2 · Sun Yat-sen University
- Apr 2027Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With ImmunotherapyPhase 1/2 · Baohui Han
- Apr 2027NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic CancerNot applicable · Du Juan
- Jun 2027Irinotecan Liposome,Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic CancerPhase 1/2 · Harbin Medical University
Studies
Open first, then newest update. How each study uses irinotecan sucrosofate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 79
- Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid TumorsRecruitingPhase 1South Plains Oncology ConsortiumNCT02013336Written as MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
- NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar TrialRecruitingPhase 2Roswell Park Cancer InstituteNCT06821997Written as Irinotecan Sucrosofate
- Study of NALIRIFOX in Advanced Unresectable Small Bowel TumorsRecruitingPhase 2Tiago Biachi de CastriaNCT06835387Written as Nanoliposomal irinotecan
- Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric AdenocarcinomaRecruitingPhase 2University of Wisconsin, MadisonNCT04150640Written as Nal-IRI
- A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal CancerNot yet recruitingPhase 2/3Hebei Medical University Fourth HospitalNCT07585279Written as Irinotecan liposome + 5-FU/LV + Bevacizumab
- Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal CancerNot yet recruitingPhase 2Guangdong Provincial People's HospitalNCT07521605Written as Liposomal Irinotecan (nal-IRI)
- Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .RecruitingPhase 1/2National Health Research Institutes, TaiwanNCT05927857Written as nal-IRI /Experimental
- Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)RecruitingEarly Phase 1SONIRE Therapeutics Inc.NCT07033689Written as Nal-IRI/FL
- A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.Not yet recruitingPhase 2The Fourth Affiliated Hospital of Zhejiang University School of MedicineNCT07395063Written as Irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab
- Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer PatientsRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06662006Written as nal-IRI,5-fu,LV, benmelstobart, anlotinib
- NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic CancerNot yet recruitingPhase 1National Taiwan University HospitalNCT07314385Written as nanoliposomal irinotecan+5-FU+leucovorin
- Folfox+Irinotecan+Chemort In Esophageal CancerRecruitingPhase 2Massachusetts General HospitalNCT04656041Written as FOLFOX/ nal-IRI
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingPhase 2Ming-Yuan ChenNCT07070479Written as Irinotecan liposome
- Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLCRecruitingNot applicableFudan UniversityNCT06258642Written as Irinotecan Liposome
- Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NETEnrolling by invitationPhase 1/2National Health Research Institutes, TaiwanNCT05385861Written as nanoliposomal irinotecan plus carboplatin
- A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal CancerNot yet recruitingPhase 2Sanjun CaiNCT07123441Written as Bevacizumab,Irinotecan liposome (II),5-FU/LV
- Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal CancerNot yet recruitingPhase 2Liu HuangNCT07051785Written as Fruquintinib+Irinotecan Liposome+Capecitabine
- PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer TreatmentNot yet recruitingPhase 2GERCOR - Multidisciplinary Oncology Cooperative GroupNCT07028424Written as Nal-IRI
- Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing SarcomaRecruitingPhase 2Sun Yat-sen UniversityNCT06827717Written as irinotecan liposome (II) + temozolomide + fluzoparib
- Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent GliomaRecruitingPhase 2Zhifeng Tian,MDNCT06801730Written as Irinotecan liposome combined with bevacizumab
See all 79 studies that test irinotecan sucrosofate →
Given beside what is tested · 26 — irinotecan sucrosofate is usual care or a partner of the new treatment
- A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line TherapyRecruitingPhase 1/2Shenzhen Majory Biotechnology Co., Ltd.NCT07235202Written as Irinotecan Liposome Injection combined with 5-FU/LV
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2RecruitingPhase 2AstraZenecaNCT06219941Written as Nanoliposomal Irinotecan
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS MutationsRecruitingPhase 3SWOG Cancer Research NetworkNCT06998940Written as Irinotecan Sucrosofate
- Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing SarcomaRecruitingPhase 1/2St. Jude Children's Research HospitalNCT04901702Written as Onivyde
- Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNot yet recruitingPhase 2China Medical University, ChinaNCT07376499Written as Liposome Irinotecan
- Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or CetuximabRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06540326Written as irinotecan liposome (II)
- Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNot yet recruitingPhase 4China Medical University, ChinaNCT06951841Written as Liposome Irinotecan
- A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)RecruitingPhase 2Belgian Group of Digestive OncologyNCT05472259Written as Nanoliposomal irinotecan
- NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDACRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06405490Written as Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
- Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLCRecruitingPhase 2Guangzhou Institute of Respiratory DiseaseNCT06739928Written as Irinotecan liposome (II) combined with adebrelimab and carboplatin
- Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal CancerRecruitingPhase 2West China HospitalNCT06341296Written as Irinotecan Liposome
- Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal CancerNot yet recruitingPhase 1/2West China HospitalNCT06341309Written as Irinotecan Liposome
- Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic CancerRecruitingPhase 2Fudan UniversityNCT06475326Written as Irinotecan liposome
- Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and SafetyRecruitingPhase 2Jiang LongNCT06531278Written as Irinotecan liposome
- NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic CancerRecruitingPhase 2Seoul National University HospitalNCT04371224Written as Irinotecan Liposomal Injection [Onivyde]
- Newly Emerging Immunotherapy for Pancreatic Cancer TreatmentNot yet recruitingPhase 1/2Fudan UniversityNCT06370754Written as Irinotecan Liposome Injection
- Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic CancerNot yet recruitingPhase 1/2Tianjin Medical University Cancer Institute and HospitalNCT06259058Written as Irinotecan liposome injection
- A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine TreatmentCompletedPhase 3IpsenNCT04083235Written as Irinotecan Liposomal Injection
- A Study of Suizenji in Patients With Unresectable Pancreatic CancerActive, not recruitingNot applicableSONIRE Therapeutics Inc.NCT05601323Written as Nal-IRI/FL
- A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic CancerCompletedPhase 1Sumitomo Pharma America, Inc.NCT02231723Written as MM-398
Showing 20 of 26.
As the comparator · 3 — what is tested is compared with irinotecan sucrosofate
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic CancerRecruitingPhase 3NRG OncologyNCT06958328Written as Irinotecan Sucrosofate
- Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingPhase 2ImmunityBio, Inc.NCT04390399Written as Irinotecan liposome
- A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic CancerCompletedPhase 2Bristol-Myers SquibbNCT03336216Written as Onivyde
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted2
- Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal AdenocarcinomaNov 4, 2026NCT04752696
- NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary CancerOct 27, 2026NCT04005339
Codes
What other systems call irinotecan sucrosofate · ClinicalTrials.gg INT006367
- MeSH (NLM) C584112irinotecan sucrosofateOne source NLM
- UNII (FDA) OL741S3N8BIRINOTECAN SUCROSOFATEConfirmed FDA, NLM, Wikidata
- Wikidata Q27285712irinotecan sucrosofateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82676Irinotecan SucrosofateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584112 | irinotecan sucrosofate | One source NLM |
| UNII (FDA) | OL741S3N8B | IRINOTECAN SUCROSOFATE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27285712 | irinotecan sucrosofate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82676 | Irinotecan Sucrosofate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.